During the corresponding time, Aytu Biopharma Inc saw a revenue deteriorated by -34.86 % year on year, sequentially revenue fell by -20.69 %. While revenue at the Aytu Biopharma Inc's corporate clients
Aytu Biopharma Inc's Comment on Sales, Marketing and Customers
The company specializes in its core prescription business, focusing on branded central nervous system (CNS) products. It holds an exclusive commercialization agreement for EXXUA, a novel first-in-class treatment for major depressive disorder (MDD) in the United States, with a planned launch in the fourth quarter of 2025. The business portfolio includes EXXUA, an ADHD portfolio, and a pediatric portfolio. Prescription products are primarily distributed in the United States through pharmaceutical wholesalers, distributors, pharmacies, and third-party logistics providers. The ADHD portfolio features Adzenys and Cotempla, FDA-approved extended-release stimulant medications in orally disintegrating tablet form for patients aged six and older. The pediatric portfolio includes Karbinal, an extended-release antihistamine suspension for patients aged two years and older, as well as Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multivitamin products for infants and children with fluoride deficiency. Commercialization is conducted through an internal organization comprising approximately 40 sales territories for ADHD products and five for pediatric products. The Aytu RxConnect patient support program operates through over 1,000 pharmacies, providing affordable copays and access to commercially insured patients.
Aytu Biopharma Inc’s Comment on Sales, Marketing and Customers
The company specializes in its core prescription business, focusing on branded central nervous system (CNS) products. It holds an exclusive commercialization agreement for EXXUA, a novel first-in-class treatment for major depressive disorder (MDD) in the United States, with a planned launch in the fourth quarter of 2025. The business portfolio includes EXXUA, an ADHD portfolio, and a pediatric portfolio. Prescription products are primarily distributed in the United States through pharmaceutical wholesalers, distributors, pharmacies, and third-party logistics providers. The ADHD portfolio features Adzenys and Cotempla, FDA-approved extended-release stimulant medications in orally disintegrating tablet form for patients aged six and older. The pediatric portfolio includes Karbinal, an extended-release antihistamine suspension for patients aged two years and older, as well as Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multivitamin products for infants and children with fluoride deficiency. Commercialization is conducted through an internal organization comprising approximately 40 sales territories for ADHD products and five for pediatric products. The Aytu RxConnect patient support program operates through over 1,000 pharmacies, providing affordable copays and access to commercially insured patients.
Sources:
Aytu Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aytu Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aytu Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
107 %